The Current Status of Thrombolytic Therapy

Collen D. Lijnen H. R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114–24.

De Bono D. Therapeutic uses of thrombolytic drugs. In: Bloom A L Forbes C D Thomas D P Tuddenham E G D eds. Haemostasis and thrombosis, Volume 2, third edition. Edinburgh: Churchill Livingstone, 1993: 1459–72.

Breddin K. Ehrly A M Fechler L. . Die Kurzzeitfibrinolyse beim akuten Myokardinfarkt. Dtsch Med Wochenschr 1973; 98: 861–69.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 349–60.

Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–21.

LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759–66.

ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomized trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–70.

The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71–79.

Gruppo Italiano per lo Studio della Sopravivvenza nell 'Infarto Miocardio: GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65–71.

The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82.

The GUSTO Angiographic Investigators. The comparative effects of plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615–22.

Simoons M L Maggioni A P Knatterud G. . Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523–27.

Grines C L Browne K F Marco J. . A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673–79.

Gibbons R J Holmes D R Reeder G S Bailey K R Hopfenspirger M R Gersh B. J. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment of myocardial infarction. N Engl J Med 1993; 328: 685–91.

Ten Cate J. W. Thrombolytic treatment of pulmonary embolism. Lancet 1993; 341: 1515–16.

Earnshaw J J Beard J. D. Intraoperative use of thrombolytic agents. Br Med J 1993; 307: 638–39.

Refino C J Paoni N F Keyt B A . A variant of t-PA (T103N, KHRR-296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993; 70: 313–19.

Simoons M L Arnold A E R Betriu A. . Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; i: 197–203.

Lijnen H R Collen D. , Development of novel thrombolytic agents. J Int Med 1994 (in press).

Gardel S J Ramjit D R Stabilito II . Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244–53.

Collin D. Lu H R Lijnen H R Nelles L. Stassen J. M. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 1991; 84: 1216–34.

Collen D. Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850–53.